Intratumoral PH-762 for Cutaneous Carcinoma

Key Inclusion Criteria:

• Histologically confirmed cutaneous squamous cell carcinoma (cSCC), melanoma, orMerkel cell carcinoma, meeting one of the following criteria:

• cSCC, resectable local tumors: must be Stage II or lower, amenable to curativeresection and in a location where acceptable surgical margins are anticipated

• cSCC, unresectable local tumors: must be Stage II or lower, tumor has beenunresponsive to prior radiation therapy or is not a candidate for curativeradiation therapy

• cSCC, metastatic disease: disease has progressed during or following priorcheckpoint inhibitor therapy (anti-PD-1 or anti-PD-L1 antibody)

• Melanoma, metastatic disease: Stage IV disease with a cutaneous lesion that hasprogressed during or following checkpoint inhibitor therapy (anti-PD-1/-PD-L1),and if BRAF-mutation is present, has progressed during or following priortreatment with anti-BRAF + MEK therapy

• Merkel cell carcinoma, metastatic disease: Stage IV disease with a cutaneouslesion that has progressed during or following checkpoint inhibitor therapy (anti-PD-1/PD-L1)

• A minimum of one tumor of ≥ 1.0 cm and < 3.0 cm in longest dimension that isaccessible (with or without imaging guidance) for intratumoral injection and forbiopsy and surgical excision must be present. The tumor is not necrotic,hemorrhagic, or friable, and is not within 2 cm of the eye or within 0.5 cm of or onthe lip (including the vermilion border) and is not in a mucosal or viscerallocation.

Key Exclusion Criteria:

• Other malignancy within prior 3 years, with certain exceptions.

• Current cancer chemotherapy, radiation therapy, immunotherapy, or biologic therapy.

• Any serious or uncontrolled medical disorder including auto-immune disease that mayincrease the risk associated with study participation or study drug administration,or interfere with the interpretation of study results.

• Females who are pregnant or are breastfeeding.